The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

Research output: Contribution to journalArticleAcademicpeer-review

147 Citations (Scopus)


Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX.Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole peripheral blood RNA was performed by Illumina
Original languageEnglish
Article numberR95
JournalArthritis research & therapy
Issue number2
Publication statusPublished - 2012

Cite this